πŸ‡ΊπŸ‡Έ FDA

Intelligence Platform

Patents

Browse 12 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed
patent

US 11555064

Treating headache comprising administering an antibody to calcitonin gene-related peptide

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Jan 17 2023 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jan 12 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10723778

Variants of adrenomedullin and calcitonin gene-related peptide and methods of use

The Board of Regents of the University of Oklahoma Β· Granted Tue Jul 28 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jul 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10597448

Methods for treating visceral pain associated with interstitial cystitis by administering

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Mar 24 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Mar 19 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10556945

Antagonist antibodies directed against calcitonin gene-related peptide and methods using s

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Feb 11 2020 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 06 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10519224

Treating headache comprising administering an antibody to calcitonin gene-related peptide

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Dec 31 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Dec 26 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10464983

Variants of adrenomedullin and calcitonin gene-related peptide and methods of use

The Board of Regents of the University of Oklahoma Β· Granted Tue Nov 05 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Oct 31 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 10329343

Methods for treating headache using antagonist antibodies directed against calcitonin gene

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Jun 25 2019 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Jun 20 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9896502

Antagonist antibodies directed against calcitonin gene-related peptide and methods using s

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Feb 20 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 15 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9890211

Antagonist antibodies directed against calcitonin gene-related peptide

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Feb 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9890210

Antagonist antibodies directed against calcitonin gene-related peptide

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Feb 13 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 08 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9884907

Methods for treating headache using antagonist antibodies directed against calcitonin gene

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Feb 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted
patent

US 9884908

Methods for treating headache using antagonist antibodies directed against calcitonin gene

TEVA PHARMACEUTICALS INTERNATIONAL GMBH Β· Granted Tue Feb 06 2018 00:00:00 GMT+0000 (Coordinated Universal Time) Β· Expires Mon Feb 01 2038 00:00:00 GMT+0000 (Coordinated Universal Time)

granted